Chugai Pharmaceutical Co., Ltd.
Chugai Pharmaceutical develops therapies for bone metabolism and blood disorders, cancer, infectious diseases, immune system disorders, and cardiovascular, kidney, and brain diseases. Products include Neutrogin, which treats white blood cell loss related to chemotherapy; Epogin, which treats red blood cell loss caused by chronic kidney failure; Sigmart, an antianginal agent; and Alfarol for osteoporosis. Chugai Pharmaceuticals has foreign operations in Asia, Europe, and North America through subsidiaries and branch locations. Swiss drugs group Roche owns about 60% of Chugai Pharmaceutical.
Contact Details
Office Address
Chugai Pharmaceutical Co., Ltd.
1-1 Nihonbashi-Muromachi 2-Chome
Chuo-ku, Tokyo, Japan 103-8324
Phone: +81-3-3273-0554
Fax: +81-3-3281-6607
Executives
President, CEO, COO, and Director
Osamu Nagayama
Deputy President, Corporate Social Responsibility, Technolog
Motoo Ueno